PacBio vs Quanterix
PacBio reported revenue of $160 million in fiscal 2025, 1.2 times Quanterix's $139 million in fiscal 2025. PacBio's revenue grew 3.9% in its latest year, and Quanterix's grew 1.1%. PacBio had an operating margin of -346.1%, against -90.4% at Quanterix. Free cash flow was −$114 million at PacBio and −$80 million at Quanterix.
Side by side
| PacBio | Quanterix | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $160M | $139M |
| Revenue growth | 3.9% | 1.1% |
| Revenue growth a year, last 5 years | 15.2% | 10.0% |
| Gross margin | 28.6% | 46.8% |
| Operating margin | −346.1% | −90.4% |
| Net margin | −341.5% | −77.1% |
| Free cash flow | −$114M | −$80M |
| Free cash flow margin | −71.2% | −57.5% |
| Return on capital | −77.1% | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 4.0% | 11.1% |
| Last close | $1.76 | $2.03 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $1.3 million | bought $296,049, sold $0 |
| Piotroski F-score | 3 of 9 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
PacBioQuanterix
Operating margin
Percent of revenue
PacBioQuanterix
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
PacBioQuanterix